Group 1: Event Overview - The Shenzhen Stock Exchange held a special roadshow in Hong Kong titled "Investing in New Opportunities in China," featuring eight listed companies from the Shenzhen market [1] - The event aimed to showcase the investment value of high-quality assets in Shenzhen and the industrial upgrades of these companies to overseas asset management institutions [1] - Since 2023, the Shenzhen Stock Exchange has organized overseas roadshows covering 14 countries and regions, connecting over 2,000 foreign institutional investors [1] Group 2: Company Highlights - Juxing Technology operates 23 production bases globally, with over 95% of its revenue coming from overseas, making it a major supplier for top global retailers [7] - Yilian Network maintains a global market share of over 95% in SIP phones and ranks among the top five in video conferencing systems, benefiting from a dynamic order allocation mechanism [7] - Changying Precision is expanding its production bases in Vietnam and Mexico to meet the diversified supply chain needs of major clients like Apple and CATL [7] - Shenghong Technology is leading the market with advanced materials and technologies, focusing on AI-related products and sustainable development strategies [7][8] Group 3: Consumer Sector Insights - Yunnan Baiyao is projected to exceed 40 billion yuan in revenue in 2024, with a net profit of 4.75 billion yuan, showcasing a strong dividend policy and brand strength [8] - Salted Fish has established a closed-loop system for product development, achieving a rapid iteration cycle and a return on equity of 40.9%, attracting significant foreign investor interest [8] Group 4: Investor Sentiment and Future Outlook - Foreign investors remain optimistic about the Chinese stock market, anticipating a sustainable growth cycle driven by improving fundamentals and long-term growth potential [9] - The "14th Five-Year Plan" emphasizes increasing domestic consumption and technological self-reliance, which may lead to new growth opportunities in the consumer sector and for companies with strong R&D capabilities [9] - The Shenzhen Stock Exchange plans to enhance services for overseas investors and facilitate cross-border investment activities to support domestic and international economic circulation [9]

中新网昆明1月30日电 (陆希成 陈静)云南省两会期间，多位政协委员围绕中医药产业发展建言献策，探 讨如何将"厚家底"转化为"强动能"。 2025年10月18日，云南省中医医院组织中医药主题研学活动，孩子们通过沉浸式体验了解中医药文化。 云南省中医医院 供图 云南是中国中药材资源大省，全国约1.88万种药用生物资源中，云南独占8875种；全省中药材种植面积 达1072万亩，连续六年居全国首位；三七、石斛等道地药材产量占全国九成以上，中医药综合产值已突 破1800亿元。 转化则是产业链增值的核心。顾海潮指出，云南各级中医医院积累了大量经过临床验证的院内制剂，是 产品研发的宝贵"种子"。他建议建立医疗机构、科研院所与企业的协同转化机制，推动确有疗效的制剂 走向市场，实现从"病床边"到"货架上"的跨越。 农工民主党云南省委在集体提案中建议，从良种繁育、标准化体系、精深加工、研发支撑等方面系统发 力，将中药材打造成继烟草之后的又一支柱产业。 除了做强产业链，中医药与文旅康养的融合也颇受关注。云南省政协委员林德兴在提案中建议，依托云 南气候和生态优势，打造一批中医药健康旅游示范基地。 然而，亮眼数据背后也有隐忧。"我们 ...

Core Viewpoint - The Chinese medicine sector is experiencing a rebound, with the Chinese Medicine ETF (560080) showing significant inflows and a notable increase in trading volume, indicating renewed investor interest [1][5]. Group 1: Market Performance - The Chinese Medicine ETF (560080) rose by 1.34% with a trading volume of nearly 100 million yuan, reflecting a 34% increase compared to the previous period [1]. - Over the past three days, the ETF has attracted approximately 100 million yuan in investments [1]. - Key constituent stocks of the ETF, such as Pizhou Pharmaceutical, have shown strong performance, with Pizhou rising nearly 7% after a nine-day decline [5]. Group 2: Valuation Insights - The latest price-to-earnings ratio (PE-TTM) for the index tracked by the Chinese Medicine ETF is 24.23, which is below 83.95% of the time since its inception in May 2015, indicating attractive valuation [3]. - The index's valuation percentile is at 16.05%, suggesting a favorable price-performance ratio for investors [3]. Group 3: Future Outlook - The Chinese medicine sector is expected to recover in 2026 after a weak performance in 2025, driven by inventory digestion and an increase in flu incidence, which may boost demand for OTC products [7]. - Companies with strong brand power and effective inventory management are likely to benefit from the anticipated recovery in the sector [8]. - The adjustment of the essential drug list is expected to progress in 2026, potentially enhancing the accessibility of traditional Chinese medicine [8]. Group 4: Investment Recommendations - Investors are advised to focus on high-quality assets with low valuations in the Chinese medicine sector, particularly those that can effectively manage inventory and have strong brand recognition [8][9]. - The performance of companies that successfully integrate both hospital and outpatient markets is highlighted as a key factor for future growth [8].

知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 2020-2025年中国中成药产量统计图 数据来源：国家统计局，智研咨询整理 上市企业：云南白药（000538）,同仁堂（600085）,片仔癀（600436）,白云山（600332）,太极集团 （600129）,东阿阿胶（000423）,九芝堂（000989）,贵州百灵（002424）,葵花药业（002737）,吉林敖 东（000623） 相关报告：智研咨询发布的《2026-2032年中国中成药行业发展形势分析及产业前景规划报告》 根据国家统计局数据显示：2025年12月中国中成药产量为19.4万吨，同比增长2.1%；2025年中国中成药 累计产量为181.4万吨，累计下降7.7%。 ...

"AI不是替代人，而是让人从重复劳动中解放出来，成为'指挥官'。"日前在2026医药钉峰会上，钉钉大 健康行业负责人韦亚伟表示，AI正从信息、知识、数据、流程与协同五大层面，系统重构药企的工作 方式。 另据钉钉商业总裁杨猛在现场透露，目前已有超六成医药企业和超半数公立医院使用钉钉，打造全新 AI操作系统。 据了解，AI已在不同赛道医药企业的数智化浪潮中按下加速键。云南白药、信达生物、乐普生物、昭 衍新药、仙乐健康等一批代表企业已率先落地AI。 "百年老店"云南白药与钉钉共同打造了全集团的数字底座"白药钉"，数字化布局已贯穿中药材溯源、智 能工厂生产到AI辅助研发的各个环节。云南白药集团数字战略科学家李少春提出，未来的AI智能体须 具备"手和脚"，即与自动化流程和物理设备深度融合，方能释放真正的生产力。 （文章来源：中国经营报） A1录音卡能够实时捕捉并智能分析医药代表拜访场景，自动提取关键信息，生成结构化报告，使一线 市场情报得以无损耗、秒级同步至决策层，真正实现"让听见炮火的人指挥战斗"。 在数据处理与应用层面，AI带来了显著的民主化趋势。借助AI表格，业务人员无须依赖IT部门，便能 以自然语言对话的方式， ...

Core Insights - The pharmaceutical industry is increasingly adopting AI technologies, with over 60% of pharmaceutical companies and more than half of public hospitals using DingTalk as an AI operating system to enhance productivity [1][2] - AI is transforming the pharmaceutical sector by enabling companies to shift from repetitive tasks to more strategic roles, thereby enhancing operational efficiency [1][2] - DingTalk's AI application white paper indicates that AI is moving from exploration to large-scale application across the pharmaceutical value chain, impacting drug discovery, production, quality control, and patient services [1][2] Industry Developments - The pharmaceutical industry is characterized by high specialization, strong regulation, and long supply chains, making AI implementation a systemic transformation rather than just a technological upgrade [2] - DingTalk's AI solutions have been successfully implemented in various pharmaceutical companies, including WuXi AppTec and Innovent Biologics, and the company plans to launch a "Digital Pioneer Competition" to cultivate AI-savvy individuals within 100 pharmaceutical firms [2][3] - The establishment of the "Pharmaceutical Industry AI Innovation Alliance" aims to address common challenges such as data governance and ethical standards, promoting best practices for AI development in the sector [2][3] Company Case Studies - WuXi AppTec and DingTalk have developed a digital foundation called "BaiYaoDing," integrating AI into various processes, including traditional Chinese medicine traceability and smart factory production [2][3] - Innovent Biologics focuses on fine management in production through AI, achieving digitalization and transparency in anomaly handling, which has led to significant labor savings and improved quality [3] - Lepu Medical's AI initiatives provide 24/7 professional knowledge support to sales teams, resulting in a 200% return on AI investment by 2025, demonstrating AI's direct value in driving business growth [3] - Xianle Health has utilized AI tools to create an intelligent inspection application, enhancing management efficiency and fostering a culture of innovation within the organization [3][4] Future Outlook - AI is becoming a core driver of quality improvement, efficiency, and innovation in the pharmaceutical industry, with ongoing advancements in technology and a thriving ecosystem [4]

1月28日晚间，有"牙膏第一股"之称的两面针（600249）（600249）披露2025年年度业绩预告，公司预计 2025年年度实现归属于上市公司股东的净利润为500万元到1,000万元，与上年同期相比，将减少7109.88万 元到7609.88万元，同比下降87.67%至93.83%。 公开资料显示，两面针起源于1941年成立的亚洲枧厂等5家小型私营肥皂厂，1978年组建"柳州市牙膏 厂"，2004年在上交所挂牌上市，是A股牙膏行业首家自有品牌上市企业，其牙膏销量曾连续10数年居全 国第一，有"牙膏第一股"之称，其广告拥有较高的国民记忆度。两面针主营业务是日化用品的研发、生产 和销售。公司的主要产品是两面针、沐兰泽、逍遥、芳草等。 此前于2025年10月28日，两面针公布2025年三季报，公司前三季营业收入为8.15亿元，同比上升3.03%； 归母净利润为2349万元，同比下降72.04%；扣非归母净利润为1550万元，同比下降44.81%。其中第三季 度，公司营业收入为2.93亿元，同比上升6.83%；归母净利润为2857万元，同比下降67.34%；扣非归母净 利润为1069万元，同比下降44.16%。 ...

Investment Rating - The report does not explicitly state an investment rating for the biopharmaceutical industry or Fitinib Core Insights - The report focuses on the market dynamics of Fitinib in China, including sales volume and revenue changes, as well as the impact of various factors such as market competition and healthcare policies [4][6][14] Summary by Sections Market Dynamics - In August 2025, the National Healthcare Security Administration released a preliminary review of the new medical insurance drug list, which included several innovative cancer drugs, raising concerns about changes in the healthcare payment structure [6] - The sales volume of Fitinib has shown significant fluctuations since 2025, influenced by market promotion, competition, and healthcare policies [7][9] - The sales volume for Fitinib in January 2025 was 15,265 boxes for the 1mg specification, which saw a decline of 22.0% in February, followed by a recovery in subsequent months [8][9] - The 5mg specification experienced more volatility, with sales dropping to a low of 4,015 boxes in March 2025 before rebounding [9] Sales Revenue - The sales revenue for Fitinib also exhibited notable fluctuations, with the 1mg specification reaching 3,863.0 million yuan in August 2025 after a decline in July [15][16] - The 5mg specification's revenue followed a similar pattern, indicating a competitive market landscape and the impact of healthcare policy adjustments on patient medication choices [16] - From August 2020 to August 2025, the sales revenue for the 1mg specification grew significantly in earlier years but saw a decline of 16.1% in August 2025, ending a five-year growth trend [21] Research and Development Progress - Fitinib has shown preliminary efficacy when combined with other treatments for locally advanced rectal cancer, with a complete resection rate of 100% among patients receiving the treatment [26][28] - The safety profile of Fitinib in combination therapies has been manageable, with most adverse events being of grade 1 or 2, indicating a favorable safety margin [27][28] - Ongoing studies are expected to provide further insights into the drug's efficacy and safety in various treatment regimens [28][32] Competitive Landscape - The report highlights the increasing competition in the pharmaceutical market, with multinational companies accelerating their investments and collaborations in China [6][22] - The emergence of new treatment modalities, such as antibody-targeted conjugates (ATTC), is reshaping the competitive landscape, offering potential advantages over traditional therapies [22]

Group 1 - Yunnan Province ranks first globally in the production of tin, indium, and germanium, and has the most complete platinum group metals and titanium industry chain in China [2][3] - The province is recognized as a major agricultural hub in China, with significant achievements in highland characteristic agriculture, including the highest global production of flowers and the largest number of organic product certifications in China [2][3] - Yunnan is a leader in ecological civilization, achieving the highest ranking in China for the assessment of civilized, healthy, and environmentally friendly lifestyles for two consecutive years, and aims for a 98.9% rate of good air quality days by 2025 [3] Group 2 - Yunnan Baiyao has been recognized as the world's first "Lighthouse Factory" in the field of traditional Chinese medicine health products, showcasing the highest level of intelligent manufacturing and digitalization [4] - The province has established a new advantage in "green electricity + advanced manufacturing," with major hydropower projects like the Wudongde and Baihetan power stations contributing to a total installed capacity exceeding 170 million kilowatts, ranking high in green electricity capacity and proportion in China [4]

Core Viewpoint - The pharmaceutical sector is experiencing fluctuations, with the medical ETF (159929) showing a decline of 1.16% amidst a net inflow of nearly 60 million yuan, indicating ongoing investment interest despite market corrections [1][3]. Group 1: Market Performance - The Shanghai Composite Index has seen a rise, while the pharmaceutical sector is undergoing a pullback, with the medical ETF (159929) recording a trading volume exceeding 120 million yuan [1]. - Major stocks within the medical ETF have mostly declined, with notable drops including over 3% for United Imaging Healthcare and over 2% for Mindray Medical [3]. Group 2: Company Performance and Projections - CITIC Securities expresses optimism for leading pharmaceutical e-commerce platforms, highlighting their resource advantages and AI capabilities, which are expected to enhance revenue through AI medical applications [5]. - According to Everbright Securities, WuXi AppTec's companies have reported strong earnings forecasts, with WuXi AppTec expected to achieve revenue of 45.456 billion yuan in 2025, reflecting a year-on-year growth of 15.84% [5]. - WuXi Biologics anticipates adding 209 comprehensive projects in 2025, with two-thirds being dual-targeted antibodies and ADC drugs, indicating robust growth potential [5]. Group 3: Investment Trends and Strategies - Everbright Securities suggests that future investments in the pharmaceutical sector should focus on clinical value, emphasizing the importance of addressing clinical needs amid evolving domestic and international policies [6]. - CITIC Jinshi identifies four main investment themes for 2026: innovation, international expansion, marginal changes, and consolidation within the pharmaceutical industry [7]. - The innovation theme is particularly highlighted, with expectations for improved global liquidity and supportive national policies for innovative assets, including advanced technologies in pharmaceuticals and medical devices [8].